Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Diluted EPS of $1.21 per share for fiscal year 2025.
TEVA PHARMACEUTICAL INDUSTRIES LTD Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $1.21 | +183.4% |
| 2024 | -$1.45 | -190.0% |
| 2023 | -$0.50 | +77.3% |
| 2022 | -$2.20 | -678.9% |
| 2021 | $0.38 | +110.4% |
| 2020 | -$3.64 | -300.0% |
| 2019 | -$0.91 | +61.3% |
| 2018 | -$2.35 | +85.5% |
| 2017 | -$16.26 | -23328.6% |
| 2016 | $0.07 | -96.2% |
| 2015 | $1.82 | -48.9% |
| 2014 | $3.56 | +138.9% |
| 2013 | $1.49 | -33.8% |
| 2012 | $2.25 | -27.2% |
| 2011 | $3.09 | -15.8% |
| 2010 | $3.67 | +64.6% |
| 2009 | $2.23 | +197.3% |
| 2008 | $0.75 | -68.2% |
| 2007 | $2.36 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.37 | +194.9% | +54.2% |
| June 30, 2025 | $0.24 | +132.0% | +33.3% |
| March 31, 2025 | $0.18 | +250.0% | +146.2% |
| September 30, 2024 | -$0.39 | -750.0% | +48.0% |
| June 30, 2024 | -$0.75 | +3.8% | -525.0% |
| March 31, 2024 | -$0.12 | +40.0% | -300.0% |
| September 30, 2023 | $0.06 | +20.0% | +107.7% |
| June 30, 2023 | -$0.78 | -271.4% | -290.0% |
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +183.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2007–2025 period, TEVA PHARMACEUTICAL INDUSTRIES LTD’s diluted eps has declined by 48.7% (from $2.36 per share to $1.21 per share).
- The most recent figure is from TEVA PHARMACEUTICAL INDUSTRIES LTD’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: